Martin Bauer Group has acquired plant-based ingredients manufacturer BI Nutraceuticals as it targets accelerated growth in the US.
Based in California, BI Nutraceuticals supplies a range of botanical, nutritional and value-added ingredients for the food and beverage, dietary supplement and personal care industries.
Botanical ingredients provider Martin Bauer said the acquisition will create “an extensive portfolio of botanical ingredients and a versatile manufacturing hub”. As part of the deal, the two companies will continue to operate independently.
Ennio Ranaboldo, CEO of Martin Bauer Group in North America, said: “The addition of BI Nutraceuticals to our group buttresses our commitment to reliable, quality, safe and clean-label raw materials, meeting an increasing demand from our customers and consumers.”
BI Nutraceuticals CEO George Pontiakos said: “This represents a significant move forward for us and our combined customer base. The Martin Bauer Group is a family-owned international company with a long history as a manufacturer and supplier of teas, extracts and botanical products going back more than 135 years.
“BI Nutraceuticals will now have access to the global resources of the Martin Bauer Group in the areas of raw materials sourcing, processing technology, liquid extract production and research and development.
“As part of the Martin Bauer Group, we become a true single-source solution provider. Our customers can be even more confident in our long-standing commitment to safety, quality, service and innovation.”
With products sourced from more than 80 countries, Martin Bauer has more than 20 manufacturing sites and sales units worldwide. The company has around 3,600 employees.
Last December, the firm doubled the size of its tea extract manufacturing facility in Hangzhou, China. The new 200,000-square-foot unit expands the site’s capacity for green and black tea extracts to meet rising global demand.
By Jules Scully
The company expects to eliminate 1.2 billion tons carbon dioxide equivalent of methane emissions by the end of the decade. The company says that it already reduced its methane emissions by around 14% between 2018 and 2020.
The “first-of-its-kind” pilot project will develop and demonstrate an affordable modular bioprocessing system to produce biodegradable bioplastics from food waste diverted from landfills. The three-year grant will test the scalability and feasibility of the conversion on a national and global scale.
Arkeon is allying with specialty mineral giant ICL to support the scaling of its fermentation bioprocess that converts CO2 into the 20 proteinogenic essential amino acids needed in human nutrition. The process, hailed as carbon negative, is based on the use of archaea, a group of microorganisms that naturally feeds off the greenhouse gas.